Product Offerings

MolecularMD has developed sensitive and highly reliable protein and molecular assays, designed to detect targets within blood based and solid tumor malignancies. A test menu of CLIA and RUO offerings exists with various diagnostic test types, to include SNPs, INDELs, copy number variations, translocations and/or expression levels. All diagnostic assays are optimized to provide the largest amount of diagnostic yield possible. Template expertise includes formalin-fixed paraffin-embedded tissue (FFPE), bone marrow, fine needle aspirates, core biopsies and peripheral blood. With MolecularMD’s primary focus in oncology, our diagnostic tests target novel as well as known clinically relevant cancer biomarkers.

MolecularMD’s platform-agnostic laboratory tests span the following technologies:

  • Next Generation Sequencing (NGS)
  • Droplet digital PCR (ddPCR)
  • qPCR
  • RT-qPCR
  • Allele-Specific PCR
  • Sanger Sequencing
  • Capillary Electrophoresis Fragment Analysis
  • Immunohistochemistry (IHC)
  • Digital Imaging

NGS Biomarker Panels

MolecularMD’s NGS service offering provides validated and optimized panels covering cancer oncogenes, tumor suppressors, hot spot mutations, gene copy number…


As a complement to our product offerings in nucleic acid assay quantification and analyses, MolecularMD also provides Immunohistochemistry (IHC) assay…

Liquid Biopsy

Rare mutations often found in cancer patients may define patient selection for clinical trials, personalized drug treatment, and measurement of drug efficacy…


Immuno-Oncology (I-O) is one of the most promising areas for the development of new therapies. IO therapies can harness the power of the body’s immune…